biophytis is a biotech company developping therapeutics for aging diseases. it that has been created in 2006 as a spin-off of université pierre et marie curie (paris). biophytis has developped a portfolio of drug candidates at clinical stage for the treatment of sarcopenic obesity (bio101, bio103) and dry age-related macular degeneration (bio201).
Company profile
Ticker
BPTS
Exchange
Website
CEO
Stanislas Veillet
Employees
Incorporated
Location
Industry (SIC)
SEC CIK
BPTS stock data
Latest filings (excl ownership)
6-K
Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity
18 Apr 24
6-K
Biophytis files a patent application and strengthens its intellectual property in obesity
15 Apr 24
6-K
Biophytis announces its 2023 financial results
9 Apr 24
6-K
Biophytis launches OBA phase 2 clinical study
9 Apr 24
20-F
2023 FY
Annual report (foreign)
8 Apr 24
6-K
All resolutions presented by the Company have been adopted
5 Apr 24
6-K
Biophytis presented its phase 3 protocol in the treatment of sarcopenia
22 Mar 24
6-K
Biophytis announces the implementation
18 Mar 24
6-K
Current report (foreign)
18 Mar 24
6-K
Biophytis announces its participation in several events in Europe and the United States over the coming months
12 Mar 24
Latest ownership filings
No filings
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q2 2023
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 2 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 332.00 k |
Total shares | 145.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
MS Morgan Stanley | 100.00 | $229.00 k |
UBS UBS Group AG - Registered Shares | 45.00 | $103.00 k |
Proequities | 0.00 | $0.00 |